Glaukos (NYSE:GKOS)‘s stock had its “buy” rating reiterated by analysts at BMO Capital Markets in a research report issued on Monday.

Several other equities research analysts have also commented on the stock. Zacks Investment Research upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a report on Monday, November 13th. Stephens restated an “overweight” rating and issued a $40.00 price target (down previously from $47.00) on shares of Glaukos in a report on Monday, November 13th. Cantor Fitzgerald restated a “buy” rating and issued a $60.00 price target on shares of Glaukos in a report on Tuesday, November 7th. BidaskClub lowered shares of Glaukos from a “buy” rating to a “hold” rating in a report on Monday, September 18th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $38.00 price target on shares of Glaukos in a report on Friday, September 15th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $46.57.

Shares of Glaukos (GKOS) traded down $1.11 on Monday, reaching $24.85. 2,324,900 shares of the company were exchanged, compared to its average volume of 646,691. Glaukos has a one year low of $23.07 and a one year high of $52.49. The company has a market cap of $897.32, a price-to-earnings ratio of 216.33 and a beta of 1.02.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.06. Glaukos had a negative net margin of 0.64% and a positive return on equity of 3.50%. The company had revenue of $40.41 million during the quarter, compared to analyst estimates of $38.69 million. During the same quarter last year, the business posted $0.03 EPS. The firm’s revenue for the quarter was up 36.6% on a year-over-year basis. analysts expect that Glaukos will post -0.03 EPS for the current fiscal year.

In other news, CFO Joseph E. Gilliam acquired 2,100 shares of Glaukos stock in a transaction that occurred on Wednesday, November 22nd. The stock was purchased at an average price of $23.84 per share, for a total transaction of $50,064.00. Following the purchase, the chief financial officer now directly owns 102,100 shares in the company, valued at approximately $2,434,064. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 16.40% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in GKOS. Ameritas Investment Partners Inc. grew its position in Glaukos by 93.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 1,212 shares during the last quarter. Valeo Financial Advisors LLC purchased a new stake in Glaukos during the 3rd quarter worth approximately $111,000. BNP Paribas Arbitrage SA grew its position in Glaukos by 740.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock worth $147,000 after purchasing an additional 3,118 shares during the last quarter. Quantbot Technologies LP grew its position in Glaukos by 291.3% during the 3rd quarter. Quantbot Technologies LP now owns 7,653 shares of the medical instruments supplier’s stock worth $252,000 after purchasing an additional 5,697 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Glaukos during the 2nd quarter worth approximately $262,000. 99.23% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Glaukos’ (GKOS) Buy Rating Reiterated at BMO Capital Markets” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/12/glaukos-gkos-buy-rating-reiterated-at-bmo-capital-markets.html.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Analyst Recommendations for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.